SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!
菜菜
Lv1
20 积分
2023-10-11 加入
最近求助
最近应助
互助留言
Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4)
5天前
已完结
First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial
5天前
已完结
Chinese expert consensus on the diagnosis and treatment of HER2‐altered non–small cell lung cancer
5天前
已完结
Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
6天前
已完结
B-cell non-Hodgkin lymphomas
13天前
已完结
Clinical pharmacokinetics and pharmacodynamics of ivosidenib in Chinese patients with relapsed or refractory IDH1-mutated acute myeloid leukemia
14天前
已完结
[Expert consensus on the diagnosis and treatment in advanced non-small cell lung cancer with BRAF mutation in China]
16天前
已完结
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges
17天前
已完结
First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
21天前
已完结
[Clinical pathway in Chinese county for lung cancer diagnosis and treatment (2023 edition)]
25天前
已完结
没有进行任何应助
7小时未得到回应【积分已退回】
27天前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论